By Mike Ward
Editor, Europe

OXFORD - Plans by the London and Frankfurt stock exchanges to link up their high growth markets with NASDAQ will create some interesting challenges for Europe's biotech industry. While new market should provide European companies with access to deeper pools of capital, the companies could find themselves baking under the spotlight of global scrutiny.